€30.20
0.67%
Xetra, Apr 17, 05:36 pm CET
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

BIOTEST AG Stock price

€30.20
+0.80 2.72% 1M
+2.50 9.03% 6M
+3.20 11.85% YTD
+1.30 4.50% 1Y
-6.20 17.03% 3Y
+8.60 39.81% 5Y
-71.25 70.23% 10Y
Xetra, Closing price Thu, Apr 17 2025
+0.20 0.67%
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

Key metrics

Market capitalization €1.20b
Enterprise Value €1.75b
P/E (TTM) P/E ratio 45.27
EV/Sales (TTM) EV/Sales 2.41
P/S ratio (TTM) P/S ratio 1.65
P/B ratio (TTM) P/B ratio 2.25
Dividend yield 0.13%
Last dividend (FY24) €0.04
Revenue growth (TTM) Revenue growth 6.09%
Revenue (TTM) Revenue €726.20m
EBIT (operating result TTM) EBIT €78.80m
Cash position €119.30m
EPS (TTM) EPS €0.67
Show more

Is BIOTEST AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

BIOTEST AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

Hold
100%

Financial data from BIOTEST AG

Dec '24
+/-
%
Net Profit 26 26
79% 79%
4%
Depreciation and Amortization 41 41
13% 13%
6%
Stock Compensation - -
-
-
Operating Cash Flow 62 62
3,975% 3,975%
9%
Investments 29 29
14% 14%
4%
Dividend Paid 1.60 1.60
-
0%
Free Cash Flow 37 37
208% 208%
5%

In millions EUR.

Don't miss a Thing! We will send you all news about BIOTEST AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BIOTEST AG Stock News

AD HOC NEWS
20 days ago
Biotest AG / DE0005227235
AD HOC NEWS
20 days ago
Biotest AG / DE0005227235
AD HOC NEWS
20 days ago
Biotest AG / DE0005227235
More BIOTEST AG News

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,495
Founded 1946
Website www.biotest.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today